Development of a Metabolically Active, Non-Replicating Sporozoite Vaccine to Prevent Plasmodium falciparum Malaria

摘要

Immunization of volunteers by the bite of mosquitoes carrying radiation-attenuated Plasmodium falciparum sporozoites protects greater than 90% of such volunteers against malaria, if adequate numbers of immunizing biting sessions and sporozoite- infected mosquitoes are used. Nonetheless, until recently It was considered impossible to develop, license and commercialize a live, whole parasite P. falciparum porozoite (PfSPZ) vaccine . In 2003 Sanaria scientists reappraised the potential impact of a metabolically active , non-replicating PfSPZ vaccine, and outlined the challenges to producing such a vaccine. Six years later, significant progress has been made in over coming these challenges. This progress has enabled the manufacture and release of multiple clinical lots of a I' generation metabolically active, non - replicating PfSPZ vaccine, the Sanariar PfSPZ Vaccine , submission of a successful Investigational New Drug application to the US Food and Drug Administration, and initiation of safety, immunogenicity and protective efficacy studies in volunteers in MD, US. Efforts are now focused on how best to achieve submission of a successful Biologics License Application and introduce the vaccine to the primary target population of African children in the shortest possible period of time. This will require implementation of a systematic, efficient clinical development plan. Short term challenges include optimizing the (I) efficiency and scale up of the manufacturing process and quality control assays, (2) dosage regimen and method of administration, (3) potency of the vaccine, and (4) logistics of delivering the vaccine to those who need it most, and finalizing the methods for vaccine stabilization and attenuation. A medium term goal is to design and build a facility for manufacturing highly potent and stable vaccine for puvitol Phase 3 studies and commercial launch.